Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04154332 · ClinicalTrials.gov registry record

Exosome Cargo From Preeclampsia Patients

A clinical trial of Preeclampsia, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
64
Enrollment target
1
Study location

NCT04154332: Recruiting study of Preeclampsia, sponsored by University of Alabama at Birmingham.

NCT04154332 is a study of Preeclampsia that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 64 participants, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04154332, a study of Preeclampsia, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
64 participants
Enrollment target
1
Study location

Study Summary

Although extensively studied, the cause of preeclampsia remains uncertain other than it is thought that the placenta plays a critical role in the development of preeclampsia. Recent data revealed that exosomes released from the placenta could cause preeclampsia by transporting specific cargo responsible for the pathophysiological changes associated with the systemic disease. By isolating these exosomes from maternal blood and placental tissue in patients diagnosed with preeclampsia and studying their biochemical, cellular and molecular mechanism in an animal model, the investigators hope to elucidate the critical role that exosomal cargo plays in the development of preeclampsia and cardiovascular remodeling. This will be accomplished by obtaining patient samples from volunteers delivering at the Women and Infants Center and taking the samples to the lab for quantification, characterization, and identification of key functional roles through in/ex vivo, in vitro, and profiling studies. The investigators believe this work will be valuable as hope exists to define the functional role exosomes play in the development of preeclampsia that leads to cardiovascular remodeling. Data from this study will shed more light on the functional role of exosomal cargo in normal and pathological pregnancies and point towards novel therapeutic intervention strategies for preeclampsia associated with cardiovascular disease.

Primary Outcome

Researchers and investigators will attempt to quantify the amount of exosome abnormalities that may be present among patient populations who exhibit the preeclampsia phenotype.

Conditions Studied

Interventions

  • OTHER Sample collection

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2019-12-02
Est. Completion 2026-12-15
University of Alabama at Birmingham

1,160 total trials

What NCT04154332 shows while recruiting

NCT04154332 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,125-participant average among 48 other Preeclampsia trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Sample collection is the first listed.

NCT04154332 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT04154332 about?

NCT04154332 is a clinical study titled "Exosome Cargo From Preeclampsia Patients". Although extensively studied, the cause of preeclampsia remains uncertain other than it is thought that the placenta plays a critical role in the development of preeclampsia. Recent data revealed that exosomes released from the placenta could cause preeclampsia by transporting specific cargo respons...

What is the current status of trial NCT04154332?

This trial is currently recruiting. The enrollment target is 64 participants. The study started on 2019-12-02. Estimated completion is 2026-12-15.

What conditions does trial NCT04154332 study?

This clinical trial studies the following conditions: Preeclampsia.

What interventions are being tested in trial NCT04154332?

The interventions under investigation include: Sample collection (OTHER).

Who is sponsoring clinical trial NCT04154332?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04154332 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Preeclampsia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04154332's enrollment target sits among peer trials

64 36th of 48 higher than 13 of 48 other Preeclampsia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04154332, the US trial registry maintained by the National Library of Medicine. NCT04154332 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.